Method for determining prognosis of breast cancer

A 27-gene method for breast cancer prognosis improves diagnostic accuracy in low-risk groups by calculating a TP53 signature score, facilitating precise treatment strategies and drug sensitivity assessment.

JP7587251B2Active Publication Date: 2024-11-20TOHOKU UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2020141720
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-08-25
Publication Date
2024-11-20
Estimated Expiration
2040-08-25

AI Technical Summary

Technical Problem

Current methods for determining breast cancer prognosis, particularly in specific patient groups such as ER-positive, Stage I, lymph node-negative, Grade 1, over 50 years old, and Ki-67 ≥ 10%, suffer from low diagnostic accuracy and reliability.

Method used

A method utilizing a specific set of 27 genes (ASPM, BCL11A, BIRC5, C10orf3, CCNB2, CDC45L, CDCA8, CENPF, FLJ10719, FLJ11280, FLJ14399, HIS1, HSPC150, KIF2C, PKMYT1, PLK, PRC1, STMN1, TGS, UBE2C, FLJ11280, FLJ14399, HIS1, LOC51161, MGC7036, MKNK2, PTP4A2, RPS27L, SULF2) to calculate a TP53 signature score, where a good prognosis is indicated by a score less than a cutoff value, simplifying the diagnostic process.

Benefits of technology

The method provides high-accuracy prognosis prediction in patient groups with a relatively low risk of recurrence, enabling tailored treatment strategies and improved prediction of sensitivity to anticancer drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587251000003
    Figure 0007587251000003
  • Figure 0007587251000004
    Figure 0007587251000004
  • Figure 0007587251000005
    Figure 0007587251000005
Patent Text Reader

Abstract

To provide a new method for determining the prognosis of breast cancer.SOLUTION: A method for determining the prognosis of breast cancer uses all of the following 27 gene groups as an index: ASPM, BCL11A, BF930764, BIRC5, C10orf3, CCNB2, CDC45L, CDCA8, CENPF, FLJ10719, FLJ11280, FLJ14399, HIS1, HSPC150, KIF2C, LOC51161, MGC7036, MKNK2, PKMYT1, PLK, PRC1, PTP4A2, RPS27L, STMN1, SULF2, TGS, UBE2C.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for determining the prognosis of breast cancer. [Background technology]

[0002] Structural mutations in the TP53 gene are known as an independent prognostic factor for breast cancer, but because there is no simple and reliable diagnostic method, they have not been introduced into clinical practice. The present inventors have developed a gene expression profile (TP53 signature) that can predict the presence or absence of loss-of-function mutations in the TP53 gene by comprehensive gene expression analysis, and obtained a patent (Patent Document 1). In the method described in Patent Document 1, the TP53 signature status of a tumor is determined by calculating a correlation coefficient between the gene expression profiles of the TP53 gene mutant and wild type. In order to calculate the correlation coefficient, it is necessary to standardize the gene expression data of the tumor, and expression data of a large number of breast cancer cases to be compared are required for standardization. Since a large number of cases to be compared are required, the standardization algorithm is complicated, and there is a possibility that excessive data correction may occur due to standardization, a diagnostic method that improves these points was investigated. As a result, a method was reported in which the ratio of the sum of the expression levels of genes whose expression is increased in the TP53 gene mutant type to the sum of the expression levels of genes whose expression is decreased is calculated, and a TP53 signature mutant type is diagnosed when the ratio is equal to or greater than the cutoff value, and a TP53 signature wild type is diagnosed when the ratio is equal to or less than the cutoff value (Non-Patent Document 1).

[0003] However, this method had issues with its diagnostic accuracy in ER-positive patient groups, Stage I patient groups, lymph node-negative patient groups, Grade 1 patient groups, patient groups over 50 years of age, and patient groups with Ki-67≧10%. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Patent No. 4370409 [Non-patent literature]

[0005] [Non-Patent Document 1] Oncotarget 9: 14193-14206. 2018 Summary of the Invention [Problem to be solved by the invention]

[0006] An objective of the present invention is to provide a new method for determining the prognosis of breast cancer. Another objective of the present invention is to provide a method capable of diagnosing the prognosis with high accuracy, particularly in a group of breast cancer patients with a relatively low risk of recurrence. [Means for solving the problem]

[0007] Under such circumstances, the present inventors have found that the above-mentioned problems can be solved in a very simple manner by focusing on a specific gene among the wide variety of genes whose expression levels are affected by the presence or absence of a pathological mutation in the TP53 gene, and have thus completed the present invention. Accordingly, the present invention provides the following: Item 1. A method for determining the prognosis of breast cancer using all of the following 27 gene groups as indicators: ASPM (SEQ ID NO: 1) BCL11A (SEQ ID NO:2) BF930764 (SEQ ID NO: 3) BIRC5 (SEQ ID NO: 4) C10orf3 (SEQ ID NO:5) CCNB2 (SEQ ID NO:6) CDC45L (SEQ ID NO: 7) CDCA8 (SEQ ID NO: 8) CENPF (SEQ ID NO: 9) FLJ10719 (SEQ ID NO: 10) FLJ11280 (SEQ ID NO: 11) FLJ14399 (SEQ ID NO: 12) HIS1 (SEQ ID NO: 13) HSPC150 (SEQ ID NO: 14) KIF2C (SEQ ID NO: 15) LOC51161 (SEQ ID NO: 16) MGC7036 (SEQ ID NO: 17) MKNK2 (SEQ ID NO: 18) PKMYT1 (SEQ ID NO: 19) PLK (SEQ ID NO: 20) PRC1 (SEQ ID NO:21) PTP4A2 (SEQ ID NO: 22) RPS27L (SEQ ID NO: 23) STMN1 (SEQ ID NO:24) SULF2 (SEQ ID NO:25) TGS (SEQ ID NO:26) UBE2C (SEQ ID NO:27) Item 2. The method according to Item 1, wherein the prognosis is judged to be good when the TP53 signature score calculated by the following formula is less than a cutoff value: TP53 signature score = [sum of logarithms of expression values ​​of gene group A below] / [sum of logarithms of expression values ​​of gene group B below] Gene group A ASPM (SEQ ID NO: 1) BCL11A (SEQ ID NO:2) BF930764 (SEQ ID NO: 3) BIRC5 (SEQ ID NO: 4) C10orf3 (SEQ ID NO:5) CCNB2 (SEQ ID NO:6) CDC45L (SEQ ID NO: 7) CDCA8 (SEQ ID NO: 8) CENPF (SEQ ID NO: 9) FLJ10719 (SEQ ID NO: 10) HSPC150 (SEQ ID NO: 14) KIF2C (SEQ ID NO: 15) PKMYT1 (SEQ ID NO: 19) PLK (SEQ ID NO: 20) PRC1 (SEQ ID NO:21) STMN1 (SEQ ID NO:24) TGS (SEQ ID NO:26) UBE2C (SEQ ID NO:27) Gene group B FLJ11280 (SEQ ID NO: 11) FLJ14399 (SEQ ID NO: 12) HIS1 (SEQ ID NO: 13) LOC51161 (SEQ ID NO: 16) MGC7036 (SEQ ID NO: 17) MKNK2 (SEQ ID NO: 18) PTP4A2 (SEQ ID NO: 22) RPS27L (SEQ ID NO: 23) SULF2 (SEQ ID NO:25) Item 3. The method according to Item 1 or 2, wherein the group of genes is derived from a sample prepared from breast cancer tissue or breast cancer cells collected from a breast cancer patient. Effect of the Invention

[0008] According to the present invention, a novel method for determining the prognosis of breast cancer can be provided. The present invention also provides a method capable of diagnosing the prognosis with high accuracy in a patient group with a relatively low risk of recurrence. [Brief description of the drawings]

[0009] [Figure 1] Top left: A graph summarizing the recurrence-free survival rate and survival time of the TP53 signature wild type group (wt group) and the TP53 signature mutant type (mt group) in 216 cases of stage I-II breast cancer. Top right: A graph summarizing the recurrence-free survival rate and survival time of the TP53 signature' wild type group (wt group) and the TP53 signature' mutant type (mt group) in 216 cases of stage I-II breast cancer. Bottom left: A graph summarizing the recurrence-free survival rate and survival time of the TP53 signature wild type group (wt group) and the TP53 signature' mutant type (mt group) in 148 cases of ER positive. Bottom right: A graph summarizing the recurrence-free survival rate and survival time of the TP53 signature' wild type group (wt group) and the TP53 signature' mutant type (mt group) in 148 cases of ER positive. [Diagram 2]Top left: A graph summarizing the recurrence-free survival rate and survival time of the TP53 signature wild type group (wt group) and TP53 signature mutant type (mt group) for 115 Stage I cases. Top right: A graph summarizing the recurrence-free survival rate and survival time of the TP53 signature' wild type group (wt group) and TP53 signature' mutant type (mt group) for 115 Stage I cases. Bottom left: A graph summarizing the recurrence-free survival rate and survival time of the TP53 signature wild type group (wt group) and TP53 signature' mutant type (mt group) for 154 lymph node metastasis-negative cases. Bottom right: A graph summarizing the recurrence-free survival rate and survival time of the TP53 signature' wild type group (wt group) and TP53 signature' mutant type (mt group) for 154 lymph node metastasis-negative cases. [Diagram 3] Top left: A graph summarizing the recurrence-free survival rate and survival time for the TP53 signature wild type group (wt group) and TP53 signature mutant type (mt group) for 55 grade 1 cases. Top right: A graph summarizing the recurrence-free survival rate and survival time for the TP53 signature' wild type group (wt group) and TP53 signature' mutant type (mt group) for 55 grade 1 cases. Bottom left: A graph summarizing the recurrence-free survival rate and survival time for the TP53 signature' wild type group (wt group) and TP53 signature' mutant type (mt group) for 149 cases aged 51 years or older. Bottom right: A graph summarizing the recurrence-free survival rate and survival time for the TP53 signature' wild type group (wt group) and TP53 signature' mutant type (mt group) for 149 cases aged 51 years or older. [Figure 4]Left: A graph summarizing the recurrence-free survival rate and survival time for the TP53 signature wild type group (wt group) and the TP53 signature mutant type (mt group) in 152 patients with Ki-67 of 10% or more. Right: A graph summarizing the recurrence-free survival rate and survival time for the TP53 signature' wild type group (wt group) and the TP53 signature' mutant type (mt group) in 152 patients with Ki-67 of 10% or more. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The present invention relates to a method for determining the prognosis of breast cancer using a specific group of genes as an index. In the present invention, the term "gene" includes not only structural genes that define the primary structure of proteins, tRNA, rRNA, etc., but also regions on nucleic acids that have specific control functions such as promoters and operators, unless otherwise specified. Therefore, in the present invention, the term "gene" refers to regulatory regions, coding regions, exons, and introns without distinction, unless otherwise specified. In addition, the term "structural gene" also includes silent DNA in which silent mutations have been made in the original DNA sequence. In addition, in the present invention, the term "gene" also includes nucleic acid molecules such as siRNA that interfere with gene expression.

[0011] In this specification, "nucleic acid" is synonymous with nucleotide, oligonucleotide, and polynucleotide, and may be any of DNA, RNA, and DNA-RNA hybrids. These may be double-stranded or single-stranded, and when a nucleic acid molecule having a certain sequence is mentioned, it is meant to comprehensively mean a nucleic acid molecule (or nucleotide, oligonucleotide, and polynucleotide) having a complementary sequence, unless otherwise specified. These nucleic acid molecules may be circular or linear, and may be synthetic or of biological origin.

[0012] Method for determining prognosis of breast cancer The present invention provides a method for determining the prognosis of breast cancer using all of the following 27 gene groups as indicators: ASPM (SEQ ID NO: 1), BCL11A (SEQ ID NO: 2), BF930764 (SEQ ID NO: 3), BIRC5 (SEQ ID NO: 4), C10orf3 (SEQ ID NO: 5), CCNB2 (SEQ ID NO: 6), CDC45L (SEQ ID NO: 7), CDCA8 (SEQ ID NO: 8), CENPF (SEQ ID NO: 9), FLJ10719 (SEQ ID NO: 10), FLJ11280 (SEQ ID NO: 11), and FLJ14399 (SEQ ID NO: 12). , HIS1 (sequence number 13), HSPC150 (sequence number 14), KIF2C (sequence number 15), LOC51161 (sequence number 16), MGC7036 (sequence number 17), MKNK2 (sequence number 18), PKMYT1 (sequence number 19), PLK (sequence number 20), PRC1 (sequence number 21), PTP4A2 (sequence number 22), RPS27L (sequence number 23), STMN1 (sequence number 24), SULF2 (sequence number 25), TGS (sequence number 26), UBE2C (sequence number 27).

[0013] In a typical embodiment of the present invention, the expression level of each of the above genes in a sample collected from a breast cancer patient is measured. Such a biological sample is not particularly limited as long as it contains nucleic acid derived from tumor cells of a breast cancer patient, and examples thereof include breast cancer tumor tissue and breast cancer tumor cells collected from the breast cancer patient. Examples of the biological sample include breast tissue, nipple secretions, blood, serum, plasma, and the like collected from the breast cancer patient. The method of extracting DNA from these samples is also not particularly limited, and can be performed using or based on a known method. The expression level of each gene can be obtained by measuring the mRNA, protein, and the like of each gene, and can be obtained, for example, by measuring mRNA as in the examples described below. The method of measuring the amount of mRNA is not particularly limited, and for example, RT-quantitative PCR, RNA-Seq, and the like can be used. The method of measuring protein is not particularly limited, and for example, ELISA, protein array, and the like can be used. The expression level can also be measured using a reporter gene assay.

[0014] In the present invention, the genes used as prognostic indicators include known genes to which Genbank Accession No. is assigned as shown below. More specifically, the base sequences of the cDNA sequences of the genes include those shown in SEQ ID NO: 1 to 27. The name of each gene, and the correspondence between the Genbank Accession No. and the SEQ ID NO: in a typical embodiment are shown in the table below.

[0015] [Table 1]

[0016] In a preferred embodiment, according to the method of the present invention, the 27 genes are divided into two groups, and the TP53 signature score, which is represented by the following formula, is calculated from the expression level of each gene. When the score is less than the cutoff value, the prognosis is judged to be good: TP53 signature score = [sum of logarithms of expression values ​​of gene group A below] / [sum of logarithms of expression values ​​of gene group B below] Genogroup A: ASPM, BCL11A, BF930764, BIRC5, C10orf3, CCNB2, CDC45L, CDCA8, CENPF, FLJ10719, HSPC150, KIF2C, PKMYT1, PLK, PRC1, STMN1, TGS, UBE2C Genogroup B: FLJ11280, FLJ14399, HIS1, LOC51161, MGC7036, MKNK2, PTP4A2, RPS27L, SULF2.

[0017] In such an embodiment, the logarithm of the expression value may be, for example, log n [Expression value] can be increased. Here, n is a preset value, and can be set, for example, within the range of 8≦n≦12, preferably within the range of 9≦n≦11, and typically n=10. In this embodiment, the cutoff value T can be set, for example, in the range of 1.50≦T≦1.80, preferably in the range of 1.60≦T≦1.70, and more preferably in the range of 1.65≦T≦1.70. In a typical embodiment of the present invention, the cutoff value T can be set to 1.67.

[0018] In a preferred embodiment of the present invention, the prognosis can be determined to be poor when the TP53 signature score is equal to or greater than the cutoff value.

[0019] According to the present invention, the prognosis of breast cancer patients can be predicted by a method based on the extremely simplified calculation formula as described above, and therefore by a very simple method. In a typical embodiment of the present invention, examples of breast cancer patients to be treated include Stage I-II breast cancer patients. Furthermore, according to the method of the present invention, the prognosis can be accurately predicted for ER-positive patient groups, Stage I patient groups, lymph node metastasis-negative patient groups, Grade 1 patient groups, patient groups over 50 years of age, and patient groups with Ki-67≧10%, which were difficult to predict by conventional methods.

[0020] An ER (estrogen receptor) positive patient is a patient in whom staining is observed by immunohistochemistry using an anti-ER antibody in breast cancer tissue. Compared with ER negative patients, ER positive patients have a good prognosis and relatively few cases of recurrence. However, recurrence occurs at a certain frequency, so a method to predict the prognosis of such patients has been eagerly awaited. A Stage I patient is a patient who is judged to be Stage I according to the criteria described in the Clinical and Pathological Breast Cancer Treatment Guidelines (Japan Breast Cancer Society) or the TNM classification of the Union for International Cancer Control (UICC). Stage I patients also have a relatively low risk of recurrence, but recurrence occurs at a certain frequency. However, it is difficult to predict the prognosis of patients with a low risk of recurrence, so a method to predict the prognosis of such patients has been awaited. A lymph node metastasis negative patient is a patient in whom swelling of the regional lymph nodes of breast cancer is not observed by imaging diagnosis such as CT, MRI, and ultrasound, or a patient in whom lymph node metastasis is not observed by pathological diagnosis of the regional lymph nodes. Although the risk of recurrence is relatively low in patients with negative lymph node metastasis, recurrence occurs at a certain frequency, and therefore a method for predicting the prognosis of such patients has been desired. Grade 1 patients refer to patients who are judged to be Grade 1 according to the criteria described in the Nottingham histological grading classification, the classification by Black et al., the classification by Le Doussal et al., and the nuclear grading classification in the "Breast Cancer Treatment Guidelines." Grade 1 patients also have a relatively low risk of recurrence, but recurrence occurs at a certain frequency. However, it is difficult to predict the prognosis of patients with a low risk of recurrence, and therefore a method for predicting the prognosis of such patients has been desired. In addition, patients over 50 years of age also have a good prognosis compared to patients under 50 years of age, and there are relatively few cases of recurrence. However, recurrence occurs at a certain frequency, and therefore a method for predicting the prognosis of such patients has been desired. Group, Ki-67≧10% refers to patients in whom the ratio of positive cells to the number of cells evaluated by immunohistochemistry using an antibody against KI67 (MKI67) protein in breast cancer tissue is 10% or more.Patients with Ki-67≧10% are a group of patients with a relatively high risk of recurrence, and therefore a method capable of predicting the prognosis of such patients has been desired. Therefore, the method of the present invention meets such a demand and is very useful. Therefore, the present invention provides a method for determining the prognosis of breast cancer in ER-positive patients, a method for determining the prognosis of breast cancer in Stage I breast cancer patients, a method for determining the prognosis of breast cancer in patients with negative lymph node metastasis, a method for determining the prognosis of breast cancer in Grade 1 breast cancer patients, a method for determining the prognosis of breast cancer in patients over 50 years of age, and a method for determining the prognosis of breast cancer in patients with Ki-67≧10%. As described above, the method of the present invention can diagnose the prognosis with high accuracy in patient groups with a relatively low risk of recurrence, such as an ER-positive patient group, a Stage I patient group, a lymph node-negative patient group, a Grade 1 patient group, and a patient group over 50 years of age. Since it was difficult to predict the prognosis in a patient group with a low risk of recurrence, the present invention is effective because it can predict the prognosis of such a patient group that was difficult to predict.

[0021] Also, as described above, according to the present invention, the prognosis of a breast cancer patient can be predicted. In general, in cancer, the higher the cell proliferation ability (the easier the cells grow), the more likely the prognosis is to be poor. Therefore, it is expected that the cancer cells of a patient whose prognosis is judged to be poor by the method of the present invention have a relatively high cell proliferation ability. On the other hand, anticancer drugs generally cause cell death by inhibiting DNA replication that occurs during cell proliferation or by suppressing proteins that act on cell division. Therefore, cells with high cell proliferation ability have the property that anticancer drugs are more effective against them. Therefore, according to the method of the present invention, it is also possible to judge the sensitivity of a breast cancer patient to treatment with an anticancer drug that has a site of action related to cell proliferation or cell division. A specific method can be performed according to the method for predicting the prognosis of a breast cancer patient, and for example, when the TP53 signature score is equal to or greater than the cutoff value, the breast cancer patient can be judged to be sensitive to the above-mentioned anticancer drug treatment. Also, for example, when the TP53 signature score is less than the cutoff value, the breast cancer patient can be judged to be less sensitive to the above-mentioned anticancer drug treatment. When the TP53 signature score is equal to or higher than the cutoff value, the disease progresses quickly and the prognosis is generally poor. However, when chemotherapy, especially treatment with anticancer drugs that act on cell proliferation or cell division, is performed, the rate of pathological complete response (pCR) is expected to be significantly higher than when the score is below the cutoff value. Therefore, when the TP53 signature score is equal to or higher than the cutoff value, it is possible to select a treatment strategy in which preoperative chemotherapy is actively performed to obtain pCR. On the other hand, when the TP53 signature score is below the cutoff value, it is possible to select a treatment strategy in which surgery is performed early without preoperative chemotherapy.

[0022] In the present invention, examples of breast cancer treatment include surgical therapy, drug therapy, and radiation therapy. In the present invention, drug therapy for breast cancer is not particularly limited, and includes hormone therapy, chemotherapy, therapy using molecular targeted drugs, and combinations thereof. Drugs used in hormone therapy are not particularly limited, and include, for example, antiestrogens such as tamoxifen, toremifene, fulvestrant, and raloxifene, and aromatase inhibitors such as anastrozole, letrozole, and exemestane. Drugs used in chemotherapy are not particularly limited, and include, for example, doxorubicin, cyclophosphamide, paclitaxel, and docetaxel. Molecular targeted drugs are also not particularly limited, and include, for example, anti-HER2 agents such as trastuzumab, pertuzumab, and lapatinib, CDK4 / 6 inhibitors such as palbociclib and abemaciclib, PARP inhibitors such as olaparib, and immune checkpoint inhibitors such as atezolizumab.

[0023] In the present invention, "a method for determining the prognosis of breast cancer using all 27 types of gene groups as indicators" includes not only methods that use only the above 27 genes as indicators, but also methods that use a gene group consisting of the 27 genes plus one or several genes (e.g., 1 gene, 2 genes, 3 genes, 4 genes) as indicators, within the scope of obtaining the effects of the present invention (within the scope of the unchanged conclusion).

[0024] According to the present invention, by using the above 27 genes as indicators, ANAPC7 (SEQ ID NO: 28), PTTG1 (SEQ ID NO: 29), CENPE (SEQ ID NO: 30), MUTYH (SEQ ID NO: 31), MGC45866 (SEQ ID NO: 32), MAPREL1 (SEQ ID NO: 33), TMSNB (SEQ ID NO: 34), TTC12 (SEQ ID NO: 35), HCAP-G (SEQ ID NO: 36), CEAL1 (SEQ ID NO: 37), FLJ33962 (SEQ ID NO: 38), GMNN (SEQ ID NO: 39), ENST00000332343 (SEQ ID NO: 40), HEC (SEQ ID NO: 41), GMPR2 (SEQ ID NO: 42), TncRNA (SEQ ID NO: 43), SMOC2 (SEQ ID NO: 44), DNAJC9 (SEQ ID NO: 45), RAD54B (SEQ ID NO: 46), CKS2 (SEQ ID NO: 47), I_960269 (SEQ ID NO: 48), BAG1 (SEQ ID NO: 49), FLJ33962 (SEQ ID NO: 50), GMNN (SEQ ID NO: 51), ENST00000332343 (SEQ ID NO: 52), HEC (SEQ ID NO: 53), GMPR2 (SEQ ID NO: 54), TncRNA (SEQ ID NO: 55), SMOC2 (SEQ ID NO: 56), DNAJC9 (SEQ ID NO: 57), RAD54B (SEQ ID NO: 58), CKS2 (SEQ ID NO: 59), I_960269 (SEQ ID NO: 60), BAG1 No. 49), AL137566 (SEQ ID NO: 50), BRRN1 (SEQ ID NO: 51), CDC2 (SEQ ID NO: 52), ZF (SEQ ID NO: 53), THC1577090 (SEQ ID NO: 54), CDKN2C (SEQ ID NO: 55), I_1842252 (SEQ ID NO: 56), SDOS (SEQ ID NO: 57), SNAPC2 (SEQ ID NO: 58), EVI2A (SEQ ID NO: 59), V4b (SEQ ID NO: 60), BC007934 ( The prognosis of breast cancer can be determined without using SEQ ID NO: 61), ECT2 (SEQ ID NO: 62), RAD21 (SEQ ID NO: 63), MCM7 (SEQ ID NO: 64), AK097469 (SEQ ID NO: 65), MGC39900 (SEQ ID NO: 66), FLJ21439 (SEQ ID NO: 67), STATIP1 (SEQ ID NO: 68), DKFZp434L142 (SEQ ID NO: 69), and PLAT (SEQ ID NO: 70) as indicators.

[0025] Breast cancer prognosis kit The present invention provides a kit for use in the method of the present invention, which contains a nucleic acid consisting of at least a part of the base sequence of any of the genes in Table 1. The kit of the present invention can be appropriately configured depending on the method, means, etc. for measuring the expression level of each of the above genes. For example, the length of the nucleic acid consisting of at least a part of the base sequence of any of the genes in Table 1 contained in the kit of the present invention can be several tens of base pairs, and the specific part (base sequence) can be appropriately prepared by a person skilled in the art based on information that can be easily obtained from various databases such as the database (Genbank) listed in Table 1. In addition, they can be used in the form of a probe in DNA chips or Northern blotting, a primer in PCR, etc., depending on the method for measuring the expression level of each gene. Furthermore, if necessary, the polynucleotide or oligonucleotide may be labeled with an appropriate labeling substance such as a radioactive substance, a fluorescent substance, or a dye.

[0026] The above kit may optionally contain other elements or components, such as various reagents, enzymes, buffer solutions, reaction plates (containers), and the like. EXAMPLES

[0027] Prognostic prediction of TP53 signature in 216 cases of stage I-II breast cancer Total RNA was extracted from formalin-fixed paraffin-embedded tissue (FFPE specimens) of breast cancer tumor tissue surgically removed from 216 cases of stage I-II breast cancer, and gene expression analysis was performed using nCounter (NanoString).

[0028] The expression values ​​of 27 genes constituting the TP53 signature (gene group A: ASPM, BCL11A, BF930764, BIRC5, C10orf3, CCNB2, CDC45L, CDCA8, CENPF, FLJ10719, HSPC150, KIF2C, PKMYT1, PLK, PRC1, STMN1, TGS, UBE2C, gene group B: FLJ11280, FLJ14399, HIS1, LOC51161, MGC7036, MKNK2, PTP4A2, RPS27L, SULF2) were measured, and the TP53 signature score was calculated from the log10 value of the obtained expression value. That is, in this embodiment, the TP53 signature score was calculated as follows: TP53 signature score = [log10 sum of expression values ​​of gene group A below] / [log10 sum of expression values ​​of gene group B below]

[0029] Among the 216 cases, those with a TP53 signature score of 1.67 or higher were classified as TP53 signature mutant type, and those with a TP53 signature score of less than 1.67 were classified as TP53 signature wild type.

[0030] As a result, there were 99 cases of TP53 signature mutation type and 117 cases of wild type, respectively. The upper left of Figure 1 shows a graph summarizing the recurrence-free survival rate and survival time of the TP53 signature wild type group (wt group) and the TP53 signature mutation type (mt group). As shown in the upper left of Figure 1, the TP53 signature mutation type had a significantly poorer prognosis (recurrence-free survival time) compared with the wild type (P = 0.0044). In this embodiment, the above method using TP53 signature as an index may be simply referred to as the "method of the embodiment".

[0031] Univariate analysis of recurrence-free survival time using the Cox proportional hazards model for clinical pathological patient background factors and TP53 signature for breast cancer showed that stage, presence or absence of lymph node metastasis, and TP53 signature were significantly associated with recurrence-free survival time. Ki-67 showed a tendency to be associated with recurrence-free survival time. Multivariate analysis using the Cox proportional hazards model using only factors that showed an association with recurrence-free survival time in the univariate analysis showed that only TP53 signature was significantly associated with recurrence-free survival time (hazard ratio 3.44, P=0.047). These results demonstrated that TP53 signature is a predictor of recurrence-free survival time.

[0032] [Table 2]

[0033] Next, the above 216 cases were diagnosed using the method described in Non-Patent Document 1. Specifically, the ratio of the sum of the expression levels of the genes whose expression is increased in the TP53 gene mutant type (gene group C: ANAPC, ASPM, BCL11A, BF930764, BIRC5, C10orf3, CCNB2, CDC45L, CDCA8, CENPE, CENPF, FLJ10719, HSPC150, KIF2C, MAPR1, MGC45866, MUTYH, PKMYT1, PLK, PRC1, STMN1, TGS, UBE2C, gene group D: FLJ11280, FLJ14399, HIS1, LOC51161, MGC7036, MKNK2, PTP4A2, RPS27L, SULF2) to the sum of the expression levels of the genes whose expression is decreased ([sum of the expression values ​​of the above gene group C] / [sum of the expression values ​​of the above gene group D]) was calculated. In this specification, [the sum of the expression values ​​of the above gene group C] / [the sum of the expression values ​​of the above gene group D] is referred to as TP53 signature'. In this method, when the ratio of the sum of the expression levels of the above gene group C and gene group D is 0.78 or more as the cutoff value, it is diagnosed as TP53 signature' mutant type, and when it is below 0.78, it is diagnosed as TP53 signature' wild type. In this embodiment, the above method using TP53 signature' as an index may be simply referred to as "Oncotarget diagnostic method". As shown in Figure 1, upper right, the TP53 signature' mutant type also had a significantly poorer prognosis (recurrence-free survival period) compared to the wild type (P = 0.033), but as described above, the predictability of prognosis was poor compared to the method of the embodiment using TP53 signature (Figure 1, upper left, P = 0.0044).

[0034] Next, of the 216 cases of Stage I-II breast cancer, 148 ER-positive cases were compared for the recurrence-free survival time between the TP53 signature mutation group and the wild type group. There were 53 TP53 signature mutations and 108 wild type cases, respectively. The results are shown in Figure 1, bottom left. The TP53 signature mutation type had a significantly poorer prognosis (recurrence-free survival time) than the wild type (P = 0.0239). In contrast, when the Oncotarget diagnostic method was performed on 148 ER-positive cases, there was no significant difference in prognosis (recurrence-free survival time) between the TP53 signature mutation type and the wild type (Figure 1, bottom right, P = 0.073).

[0035] Of 216 cases of Stage I-II breast cancer, 115 cases of Stage I were compared for recurrence-free survival between the TP53 signature mutation group and the wild type group. The results are shown in Figure 2, upper left. There were 48 cases of TP53 signature mutation and 67 cases of wild type, respectively. The TP53 signature mutation type had a significantly poorer prognosis (recurrence-free survival) than the wild type (P = 0.0239). In contrast, the results of performing the Oncotarget diagnostic method on 115 cases of Stage I showed no significant difference in prognosis (recurrence-free survival) between the TP53 signature mutation type and the wild type (Figure 2, upper right, P = 0.44).

[0036] Of 216 cases of stage I-II breast cancer, 154 cases with negative lymph node metastasis were compared for recurrence-free survival between the TP53 signature mutation group and the wild type group. There were 66 cases of TP53 signature mutation and 88 cases of wild type, respectively. The results are shown in Figure 2, bottom left. The TP53 signature mutation type had a significantly poorer prognosis (recurrence-free survival) than the wild type (P = 0.018). In contrast, the results of performing the Oncotarget diagnostic method on 154 cases with negative lymph node metastasis showed no significant difference in prognosis (recurrence-free survival) between the TP53 signature mutation type and the wild type (Figure 2, bottom right, P = 0.17).

[0037] Of 216 cases of stage I-II breast cancer, 55 cases of grade 1 were compared for recurrence-free survival between the TP53 signature mutation group and the wild type group. There were 11 cases of TP53 signature mutation and 44 cases of wild type, respectively. The results are shown in Figure 3, upper left. The TP53 signature mutation type had a significantly poorer prognosis (recurrence-free survival) than the wild type (P = 0.0002). In contrast, the Oncotarget diagnostic method was performed on 55 cases of grade 1, and there was no significant difference in prognosis (recurrence-free survival) between the TP53 signature mutation type and the wild type (Figure 3, upper right, P = 0.091).

[0038] Of 216 cases of stage I-II breast cancer, 149 cases aged 51 years or older were included in the study, and the recurrence-free survival time was compared between the TP53 signature mutation group and the wild type group. There were 74 and 75 TP53 signature mutation and wild type cases, respectively. The results are shown in the lower left of Figure 3. The TP53 signature mutation type had a significantly worse prognosis (recurrence-free survival time) than the wild type (P = 0.018).

[0039] Of 216 cases of stage I-II breast cancer, 152 cases with Ki-67 of 10% or more were included, and the recurrence-free survival time was compared between the TP53 signature mutation group and the wild type group. There were 92 cases of TP53 signature mutation and 60 cases of wild type, respectively. The results are shown in Figure 4, left. The prognosis (recurrence-free survival time) of the TP53 signature mutation type was significantly worse than that of the wild type (P = 0.017). In contrast, the results of performing the Oncotarget diagnostic method on 152 cases with Ki-67 of 10% or more showed no significant difference in prognosis (recurrence-free survival time) between the TP53 signature mutation type and the wild type (Figure 4, right, P = 0.059).

Claims

1. A method for determining prognosis of breast cancer using all of the following 27 gene groups as indicators: ASPM (SEQ ID NO: 1) BCL11A (SEQ ID NO:2) BF930764 (SEQ ID NO: 3) BIRC5 (SEQ ID NO:4) C10orf3 (SEQ ID NO:5) CCNB2 (SEQ ID NO:6) CDC45L (SEQ ID NO: 7) CDCA8 (SEQ ID NO:8) CENPF (SEQ ID NO:9) FLJ10719 (SEQ ID NO: 10) FLJ11280 (SEQ ID NO: 11) FLJ14399 (SEQ ID NO: 12) HIS1 (SEQ ID NO: 13) HSPC150 (SEQ ID NO: 14) KIF2C (SEQ ID NO: 15) LOC51161 (SEQ ID NO: 16) MGC7036 (SEQ ID NO: 17) MKNK2 (SEQ ID NO: 18) PKMYT1 (SEQ ID NO: 19) PLK (SEQ ID NO:20) PRC1 (SEQ ID NO:21) PTP4A2 (SEQ ID NO:22) RPS27L (SEQ ID NO:23) STMN1 (SEQ ID NO:24) SULF2 (SEQ ID NO:25) TGS (SEQ ID NO:26) UBE2C (SEQ ID NO:27) Measuring the expression levels of the following gene group A and gene group B in a sample collected from a breast cancer patient; The method includes a step of determining that the prognosis is good when the TP53 signature score calculated by the following formula is less than a cutoff value: TP53 signature score = [sum of logarithms of expression values ​​of gene group A below] / [sum of logarithms of expression values ​​of gene group B below] Gene group A ASPM (SEQ ID NO: 1) BCL11A (SEQ ID NO:2) BF930764 (SEQ ID NO: 3) BIRC5 (SEQ ID NO:4) C10orf3 (SEQ ID NO:5) CCNB2 (SEQ ID NO:6) CDC45L (SEQ ID NO: 7) CDCA8 (SEQ ID NO:8) CENPF (SEQ ID NO:9) FLJ10719 (SEQ ID NO: 10) HSPC150 (SEQ ID NO: 14) KIF2C (SEQ ID NO: 15) PKMYT1 (SEQ ID NO: 19) PLK (SEQ ID NO:20) PRC1 (SEQ ID NO:21) STMN1 (SEQ ID NO:24) TGS (SEQ ID NO:26) UBE2C (SEQ ID NO:27) Gene group B FLJ11280 (SEQ ID NO: 11) FLJ14399 (SEQ ID NO: 12) HIS1 (SEQ ID NO: 13) LOC51161 (SEQ ID NO: 16) MGC7036 (SEQ ID NO: 17) MKNK2 (SEQ ID NO: 18) PTP4A2 (SEQ ID NO:22) RPS27L (SEQ ID NO:23) SULF2 (SEQ ID NO:25) In the above step, "determining that the prognosis is good" means determining that the recurrence-free survival rate is high.

2. The method according to claim 1 , wherein the group of genes is derived from a sample prepared from breast cancer tissue or breast cancer cells taken from a breast cancer patient.

Citation Information

Patent Citations

  • Method for forecasting prognosis of cancer

    JP2007167058A

  • Cancer prognosis prediction method

    JP4370409B2